Deloitte and Google Cloud plan expansion into healthcare and R&D

In Silico
The news just days after a separate from the Consumer Technology Association bringing together more than 30 industry members to develop standards and best practices for AI in healthcare, including Google, IBM, Fitbit and Advamed, among others. (Pixabay / Geralt)

Deloitte and Google’s cloud computing service are expanding their work deeper into the healthcare sector, with plans to provide life sciences companies with infrastructure for artificial intelligence and data analytics.

This includes technology aimed at expediting research and development, as well as improving operations. Specifically, Google Cloud will work with Deloitte to provide more companies with its Contact Center AI solution for customer assistance programs, alongside its clinical data warehousing and processing services for genomics and medical imaging.

“Together, we plan to transform operating models across these key sectors by harnessing the power of cloud technologies and the extensive industry-specific knowledge and experience of our practitioners,” Janet Foutty, chair and CEO of Deloitte Consulting, said in a statement.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

RELATED: Amgen to consolidate its digital patient engagement systems under Deloitte banner

The collaboration also includes work in helping to modernize the retail and financial services sectors. The news was announced at Google Cloud’s annual developer conference in San Francisco, just days after a separate initiative was unveiled by the Consumer Technology Association to bring together more than 30 industry members to develop standards and best practices for incorporating AI in healthcare—including Google, IBM, Fitbit and Advamed, among others.

RELATED: WuXi NextCODE and Google Cloud partner to enhance global genomic access

Its tasks will include examining topics such as the trustworthiness, ethics and bias of AI-based algorithms, across the healthcare, fitness and wellness industries.

The initiative will be co-chaired by Pat Baird, regulatory head of global software standards at Philips, and Jerry Wilmink, chief business officer at CarePredict. The group plans to meet for the first time at CTA’s Technology & Standards forum in San Francisco this May.

RELATED: FDA lays out plans for a new review framework for AI and machine learning-based devices

“The rapid progress of AI presents great opportunities but a special challenge that needs urgent attention,” said Rene Quashie, CTA’s VP of policy, regulatory affairs and digital health.

“This unique working group represents a diverse set of stakeholders across the ecosystem, including clinicians, manufacturers, regulators, public policy and civil rights organizations,” Quashie said. “The work produced will provide an informed framework for the use of AI in the context of healthcare.”

Suggested Articles

In a mix-up of trial-based solutions, CRO Parexel is using its recent partnership with Datavant to run a pact with life science data firm TriNetX.

Pfizer is deepening its already long-term investment and partnership strategy with U.K.-based biotech Mission.

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.